A REVIEW ON INTRANASAL DRUG DELIVERY SYSTEM: TARGETING BRAIN

Sunita Sharma

NRI Vidyadayani Institute of Science, Management and Technology

(Received on Date: 15 January 2018 Date of Acceptance: 28 March 2018)

ABSTRACT

In spite of a few restrictions, intranasal conveyance is by all accounts the most encouraging application to enhance CNS issue, including. Medications can be quickly consumed through the huge surface region of the nasal mucosa. It diminishes foundational presentation and therefore lessens the Side impacts. This course additionally has indicated clinical hugeness by lessening Adverse impacts and Toxic Effects because of diminishing in measurements. To begin with pass digestion in the liver and pre-foundational end in the GI tract can be stayed away from. The zone is appropriate for a retentive gadget and has better patient consistence. The medication focusing to the cerebrum ought to be assessed for their wellbeing and hazard advantage proportion for the patients. At present the security issue has been given extraordinary significance by the specialists amid the examination stage, and this issue will wind up plainly basic when the medication is to be conveyed is for a long haul treatment. This course has indicated extraordinary potential to straightforwardly focus on the mind with decreased fundamental reactions. Hardly any CNS drugs are as of now in advertise as their intranasal conveyance framework. However there are number of restrictions which ought to be overcome to create fruitful nose-to-mind sedate conveyance framework. Various novel plans have been utilized to target cerebrum through nasal organization. However more endeavors are expected to make this course more productive and mainstream for cerebrum focusing on.

Keywords: Introduction, Intranasal drug delivery system, Applications, Approaches

No: of References: 20

INTRODUCTION

Medication conveyance to the focal sensory system (CNS) is dependably a testing undertaking for the definition researchers in light of the nearness of blood cerebrum obstruction (BBB).Despite great advance in neurosciences and a comparing high enthusiasm for mind conveyance innovations, not very many medications have been advertised for the treatment of CNS issue. Nasal applications for conveyance to the mind have not been sought after by the pharmaceutical business since the 1980s. As of now, Nasal medication conveyance has been perceived as an exceptionally encouraging course for conveyance of helpful mixes including bio pharmaceuticals . The nasal mucosa utilized for conveying the medications for CNS issue and fundamental organization of analgesics, tranquilizers, hormones, cardiovascular medications, and antibodies, corticosteroid hormones The life structures and physiology of the nasal section demonstrate that nasal organization has potential useful points of interest for the presentation of helpful medications into the foundational course. The fixation time profiles accomplished after nasal organization are regularly like those after intravenous organization, bringing about a fast beginning of pharmacological activity[1] .

For the treatment of diabetes insipidus and oxytocin for emission of drain in light of suckling amid bosom bolstering or constriction of the uterine muscle to rush labor by nasal conveyance. the dopamine agonist apomorphine for patients with Parkinsonism. Later the utilization of the nasal course for conveyance of immunizations, particularly against respiratory diseases, for example, flu, is drawing in enthusiasm from antibody conveyance researchers [2] At present, nasal organization is utilized restoratively for the fundamental retention of medications in an assortment. The cerebrum is the most adaptable and modern organ in the body and is secured by an exceptionally powerful obstruction as BBB (Blood Brain Barrier) and BCSFB (Blood Cerebrospinal Fluid Barrier). Blood Brain Barrier (BBB) is one such boundary which isolates however not disconnects cerebrum from all other body segments. [3]

The focal sensory system is secured by BBB and BCF which control the section of mixes into the cerebrum, there by directing mind homeostasis. Hindrance limits access to mind cells of blood–borne mixes and encourages supplements basic for typical digestion to achieve cerebrum cells. This direction of the cerebrum homeostasis brings about the powerlessness of some little and extensive helpful mixes to cross the blood– mind obstruction (BBB). It is evaluated that over 98% of little sub-atomic weight drugs and basically 100% of substantial sub-atomic weight drugs (essentially peptides and proteins) produced for CNS pathologies don't promptly cross the BBB and revelation of new modalities permitting. Creature and human examinations have demonstrated that, vehicle of exogenous materials

specifically from nose to mind is a potential course to bypass the blood-cerebrum boundary [4,5]. Nose to cerebrum medicate conveyance is in all probability interceded along the olfactory and additionally trigeminal nerve pathways, situated at the top of the nasal hole as its neuroepithelium is the main piece of the CNS that is straightforwardly presented to the outer condition. Therefore, better focusing on activity can be accomplished because of direct development of medication from the submucosal space of the nose into the cerebrospinal liquid (CSF) compartment of the cerebrum [6,7]

Medication which experiences first pass digestion to stay away from this and increments there bioavailability of medication nasal course is preferred [8] . It is helpful for the medication which are dynamic at low measurements and show less oral bioavailability, for example, Protein and peptide [9] .focal sensory system infections, for example, Epilepsies, meningitis, headache, Parkinson illnesses, Alzheimer sicknesses experiences issues In focusing on in light of the vehicle through Blood Brain Barrier [10]. From writing it demonstrates that such maladies can be dealt with by transporting exogenous material to cerebrum by nose or it's a viable course by passing BBB [11] . The consequence of focus time Profile of intranasal organization medicate is like the Intravenous route [12]

Intra nasal conveyance is non invasive& effortless conveyance and it doesn't required sterile planning and it is simple strategy for tranquilize organization for patient or doctor. The nasal course offers enhance conveyance for "non-Lipinski" drug[13] . Lipophilic medication can simple cross BBB by voyaging toss Transcellular pathway.Although numerous novel nasal item for foundational conveyance on different maladies are propelled in showcase yet at the same time no medication misusing the nasal course to treat CNS illnesses. Advancement of medication conveyance toss nose to empower quick and viable focus in Brain is challenges for Researchers

FUTURE OF INTRANASAL DRUG DELIVERY

The developing pattern among tranquilize engineers is having courses of organization that are quiet neighborly and practical. This pattern will be useful as the maturing populace and oversaw mind activities drive development in home social insurance and self-organization of medication treatments for constant conditions. Medication engineers and scientists are finding that the openness and vascular structure of the nose make it an alluring course to deliver both little particle drugs and biologics, foundationally and the over the blood-cerebrum obstruction to the CNS [central anxious system]," clarified George Perros, Greystone overseeing executive. The discoveries discharged in the complete report, "Intranasal Drug Delivery: Systemic Therapies and Markets," found that intranasal conveyance will extend to the detriment of the transcendent medication conveyance techniques (oral and parenteral). Those techniques can't be promptly enhanced for the conveyance and dosing of a huge bit of the new organically determined medication

substances anticipated that would enter clinical testing later on. As of now, very nearly 2 dozen organizations are seeking after business systems situated in entire or to a limited extent on intranasal medicate conveyance advancements. These organizations are attempting to help characterize the solution plans that will majorly affect the treatment of constant conditions, neurologic clutters, viral ailments, and age-related issues later on, the Greystone official revealed.

NASAL ANATOMY AND PHYSIOLOGY

The nose is an olfactory and respiratory organ. It consists of nasal skeleton, which houses the nasal cavity. The nasal cavity has four functions:
Warms and humidifies the inspired air.
Removes and traps pathogens and particulate matter from the inspired air.
Responsible for sense of smell.
The human nasal cavity has a total volume of about 16 to 19 ml, and a total surface area of about 150 cm2 44 and is divided into two nasal cavities via the septum. The volume of each cavity is approximately 7.5 ml, having a surface area around 75 cm2 . Post drug administration into the nasal cavity, a solute can be deposited at one or more of here anatomically distinct regions, the vestibular, respiratory and olfactory region12 that are distinguished according to anatomical and histological structure table-1 along with details given below;

Olfactory region

Smell allows humans and animals with olfactory receptors to identify food, mates, predators, and provides both sensual pleasure as well as warnings of danger . The olfactory region of the two nasal passages in humans is a area of about 2.5 square centimeters containing in total of about 50 million primary sensory receptor cells. The olfactory region consists of cilia projecting down out of the olfactory epithelium into a layer of mucous which is about 60 microns thick. This mucous layer is a lipid-rich secretion that bathes the surface of the receptors at the epithelium surface. The mucous layer is produced by the Bowman's glands which reside in the olfactory epithelium. The mucous lipids assist in transporting the odorant molecules as only volatile materials that are soluble in the mucous can interact with the olfactory receptors and produce the signals that our brain interprets as odor.



The respiratory region

The nasal respiratory region, also called conchae, is the largest part of the nasal

cavity and it is divided in superior, middle and inferior turbinate's which are projected from the lateral wall. These specialized structures are responsible for humidification and temperature regulation of inhaled air. Between them there are spaces, called meatus, which are passageways where airflow is created to assure a close contact of the inhaled air with the respiratory mucosal surface.

The respiratory epithelium is made of with four types of cells are non-ciliated and ciliated columnar cells, basal cells and goblet cells. These cells facilitate active transport processes such as the exchange of water and ions between cells and motility of cilia and also to prevent drying of the mucosa by Trapping moisture in order to facilitate mucociliary clearance.

MECHANISM OF DRUG ABSORPTION FROM NOSE

1.The first mechanism includes aqueous route of transport, which is also called as the paracellular route. This is slow and passive route. inverse log-log relationship between intranasal absorption and the molecular weight of water-soluble compounds. Poor bio-availability was observed for drugs with a molecular weight greater than 1000 Daltons[14] .

2. The second mechanism is transport through a lipoidal route is known as transcellular process and is responsible for the transport of lipophilic drugs that show a rate dependency on their lipophilicity. Drugs also cross cell membranes by an active transport route via carrier-mediated means or transport through the opening of tight junctions. For example, Chitosan, a natural biopolymer opens tight junctions between epithelial cells to facilitate drug transport[15] In addition, there are various barriers in the nasal membrane for protection from the microorganisms, allergens and irritating substances from the environment that must be overcome by drugs before they can be absorbed into the systemic circulation[16].

Blood Brain Barrier (BBB)

Basal membrane and brain cells, such as pericytes and astrocytes, surrounding the endothelial cells further form and maintain an enzymatic and physical barrier known as the blood–brain barrier (BBB). BBB tight junctions are formed between endothelial cells in brain capillaries, thus preventing paracellular transport of molecules into the brain. Micro-vessels small in diameter and thin walls compared to vessels in other organs make up an estimated 95% of the total surface area of the BBB, and represent the principal route by which chemicals enter the brain. In brain capillaries, intercellular cleft, pinocytosis, and fenestrate are virtually nonexistent; exchange must pass trans-cellularly. Therefore, only lipid-soluble solutes that can freely diffuse through the capillary endothelial membrane may passively cross the BBB[17].

Drug selection properties to penetrate Blood- Brain/Blood-CSF Barriers:[18][19]

1. Smaller molecular size of drug (>300 Da).
2. Moderately lipophilic drugs are good candidates for nose to brain targeting.
3. Volume of distribution near about 1 lit/kg.

4. Drug must be not strong ligand of an efflux pump at BBB/Blood CSF barrier.

MECHANISM OF NOSE TO BRAIN DRUG TRANSPORT:[20]

It is critical to analyze the pathway/components required before tending to the conceivable outcomes to enhance transnasal take-up by the cerebrum. The olfactory locale is known to be the entryway for a medication substance to enter from nose-to-mind following nasal ingestion. In this manner, transport over the olfactory epithelium is the transcendent worry for mind focused on intranasal conveyance. Nasal mucosa and subarachnoid space; lymphatic plexus situated in nasal mucosa and subarachnoid space alongside perineural sheaths in olfactory nerve fibers and subarachnoid space seems to have correspondences between them. The nasal medication conveyance to the CNS is thought to include either an intraneuronal or e xtra neuronal pathway. A medication can cross the olfactory way by at least one system/pathways. These incorporate paracellular transport by development of medication through interstitial space of cells transcellular or straightforward dispersion over the layer or receptor/liquid stage interceded endocytosis and transcytosis by vesicle transporter and neuronal transport. The paracellular transport mechanis m/course is moderate and latent. It for the most part utilizes a fluid method of transport. Typically, the medication goes through the tight intersections and the open clefts of the epithelial cells introduce in the nasal mucosa. There is a converse log-log connection between's intranasal retention and the atomic weight of water solvent mixes. Mixes, which are very hydrophilic in nature and additionally of low sub-atomic weight, are most fitting for paracellular transport. A sharp lessening in retention and poor bioavailability was watched for the medications having sub-atomic weight more noteworthy than 1000 Da. Besides, medications can likewise cross cell layers by a bearer – interceded dynamic transport course. For instance, chitosan, a characteristic biopolymer from shellfish, extends and opens up the tight intersections between epithelial cells to encourage tranquilize transport. The transcellular transport mechanis ms/pathways chiefly incorporate transport through a lipoidal course. The medication can be transported over the nasal mucosa/epithelium by either receptor interceded endocytosis or inactive dissemination or liquid stage endocytosis transcellular course. Exceedingly lipophilic medications are relied upon to have quick/entire transnasal take-up. The olfactory neuron cells encourage the medication transport essentially to the olfactory knob.

NEEDS AND FUTURE PROSPECTIVE OF NASAL DRUG DEIVERY

In the field of drug delivery, drug delivery technologies will play a key role in the success of the industry. The need for non-invasive drug delivery systems continues due to poor acceptance and compliance with the existing delivery systems. The current needs of the industry are improved solubility/stability, biological half-life and bioavailability enhancement of poorly absorbed drugs. Key issues

facing the biopharma industry are to improve safety, improve efficacy for organ targeting, and improved compliance via sustained release or increasing residence time of drug at the site of application. New technologies include improved nasal formulations; site specific release, carrier based systems, advanced spray formulations, atomized mist technology, preservative free system and integrated formulation development are strictly needed for success of drug delivery through nasal mucosa. For success of nasal drug delivery Researchers has to on.

Development of delivery technologies to increase efficacy and reduce side effects by target delivery with variations potential of the drug. Development of new technologies to deliver macromolecules with utilization of biotechnology and high technology.

Development of integrated/improved nasal formulations.

Development of integrated device development for successful delivery of therapeutics.

CONCLUSION

The identification of ways to increase the bioavailability of drugs in the brain opens possibilities for the causal treatment of diseases associated with a deficiency in neurosteroids and neurotransmitters in the brain. Despite several limitations, intranasal delivery seems to be the most promising application to improve CNS disorders, including Multiple sclerosis, brain injuries, by medicine.Intranasal administration of therapeutic agents (i.e., drug delivery via the nose) offers several advantages over oral, intravenous, and other routes of administration. Drugs can be rapidly absorbed through the large surface area of the nasal mucosa. It reduces systemic exposure and thus reduces the Side effects. This route also has shown clinical significance by reducing Adverse effects and Toxic Effects due to decrease in dose. Although lot more information regarding this route has to be discovered to make drug delivery through this route more effective and effecious than other route. It is an challenge for researcher to make this susceptible to patients.

First-pass metabolism in the liver and pre-systemic elimination in the GI tract can be avoided. The area is well suited for a retentive device and has better patient compliance. The drug targeting to the brain should be evaluated for their safety and risk-benefit ratio for the patients. Currently the safety issue has been given great importance by the researchers during the research stage, and this issue will become critical when the drug is to be delivered is for a long term therapy. This route has shown great potential to directly target the brain with reduced systemic side effects. Few CNS drugs are already in market as their intranasal delivery system. However there are number of limitations which should be overcome to develop successful nose-to-brain drug delivery system. A number of novel formulations have been used to target brain via nasal administration. However more efforts are needed to make this route more efficient and popular for brain targeting.

REFERENCES

Corbo DC, Liu JC, Chien YW. Characterization of the barrier properties of mucosal membranes. J Pharm Sci 1990;79:202-206

Ohwaki K, Ando H, Watanabe S and Miyake Y, Effects of dose, pH and osmolarity on nasal absorption of secretin in rats. J Pharm Sci. 1985;74:550-2

Huang C, Kimura R, Nassar A, Hussain A. Mechanism of nasal drug absorption of drug II: absorption of Ltyrosine and the effect of structural modification on its absorption. J Pharm Sci, 1985, 74, 298-1301.

Pennington AK, Ratcliffe JH, Wilson CG, Hardy JG. The influence of solution viscosity on nasal spray deposition and clearance. Int J Pharm 1988; 43:221-224.

Chalton R, Mackay I, W ilson R, Cole P (1985) Double-blind, placebo controlled trial of betamethasone nasal drops for nasal polyposis. Br Med J 291:788

Homer JJ, Maughan J, Burniston M (2002) a quantitative analysis of the intranasal delivery of topical nasal drugs to the middle meatus: spray versus drop administration. J Laryngology Otol 116:10-13

Chien YW, Su KSE, Chang .Nasalsystemic drug deliver, 2nd edition, USA: Marcel Dekker; 1989.1-38, 89- 97.

Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002; 5(6):514-16

Paun J.S., Bagada A.A., Raval M.K.., Nasal Drud Delivery-As An Effective Tool For Brain Targetting-A Review.,International Journal Of Pharmaceutical And Applied Sciences/1(2)/2010;43-55

Jadhav Kisan R., GambhireManoj N., Ishaque M. ShaikhManoj N., kadamVilarsrao J. and. PisalSambhaji S, Nasal Drug Delivery System Factors Affecting and Applications, Current Drug Therapy, 2007,2,27-38

Pardride WM. Non-Invasive Drug Delivery to human brain using endogenous blood-brain barrier transport systems.pharmaceutical sciences technology today 1999;2:49-59

Illum L. Transport of drug from the nasal cavity to the central nervous system. European Journal of Pharmaceutical Sciences 2000;11:1-18.

Johanson P.H., Quay, S.C., Advances in nasal drug delivery through tight junction technology. Expert opinion.Drug Delivery 2,2005,281-298.

Pardeshi CV, Belgamwar VS (2013) Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv 10(7): 957-972.

Abhijeet D Kulkarnia, Deepak B Baria, Sanjay JSuranab, Chandrakantsing V Pardeshi (2016) In-vitro, ex-vivo and in-vivo performance of chitosan-based spray-dried nasal mucoadhesive microspheres of diltiazem hydrochloride.

Journal of Drug Delivery Science and Technology, 31: 108-117.

Ali J, Ali M, Baboota S, Sahani JK, Ramassamy C (2010) Potential of nanoparticulate drug delivery systems by intranasal administration. Curr Pharm Des 16(14): 1644-1653.

Alam MI, Beg S, Samad A, Baboota S, Kohli K, et al. (2010) Strategy for effective brain drug delivery. Eur J Pharm Sci 40(5): 385-403

Bummer PM, Physical chemical considerations of lipid based oral drug delivery, solid lipid nanoparticles, Critical Review, Therpeutic Drug Carrier System, 2004; 21(2): 1-20.

Shrikant CS, Mahale NB, Chaudhari SR, Thorat RS, Recent advances in brain targeted drug delivery system: a review, 2015; 4(5): 542-559

Bummer PM, Physical chemical considerations of lipid based oral drug delivery, solid lipid nanoparticles, Critical Review, Therpeutic Drug Carrier System, 2004; 21(2): 1-20.